Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SiSTEM-NEO: Mesenchymal Stem Cells in Neonatal Hypoxic-Ischemic Encephalopathy
NCT07018739Phase 2Not yet recruiting
- Sponsor
- Mahidol University
- Start
- Sep 2026
- Primary completion
- Dec 2032
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Wharton's jelly-derived mesenchymal stem cells with Placebo (2 arms). Primary endpoint: Composite of death or neurodevelopmental disability at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT07018739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018739.